Boston Scientific is recalling all unused Lotus Edge transcatheter aortic valve replacement (TAVR) systems and is immediately retiring the entire Lotus technology platform, including all commercial, clinical, research, development and manufacturing activities related to the Lotus TAVR technology.
The company initiated a global, voluntary recall of Lotus Edge on 17 November due to ongoing “complexities” with the valve’s product delivery system, CEO Michael Mahoney explained during a conference...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?